LIBANG owns 3 finished dosage facilities and 2 APIs plants, all of them are operated in strict conformity to GMP.
Xi’an Formulation Plant is located in the Xi`an Hi-Tech Zone, renovated in 2013, has passed CFDA inspection and obtained the national GMP certificate. There are three Small Volume Parenterals production lines dedicated for lipid injectable emulsion: two for ampoules, one for vials.
SVP Annual Production Capacities: 70 million amps/vials
Baoji Formulation Plant is located in Baoji city, Shaanxi Province, dedicated for Large Volume Parenterals production, obtained the GMP certificate in 2010.
LVP Annual Production Capacities: 8 million bottles
Hanfeng Formulation Plant is a newly GMP facilities built in 2011, equipped with Class B+A Clean Area, has 3 Small Volume injection production lines with annual production capacity of 300 million ampoules and 2 solid dosage production with annual production capacity at 900 million tablets and 240 million capsules.
Xi’an API Plant is built in 1996, occupies 10000 square meters, with workshop area of 400 square meters and clean room area of 240 square meters. The plant is constructed and managed in full compliance with international recognized cGMP, has been successfully inspected and approved by US FDA for 3 times.
Baoji API Plant is established in 2003, occupies 40680 square meters，with 4 workshops, 756 square meters clean area, has 100 tons annual product capacity.
With the corporate philosophy of “Respecting Science”, LIBANG always regards R&D as the driving force of progress and development, has established a unique R&D platform aimed for generic drugs and innovative drugs, from API process development to large molecule biopharmaceutical drugs and specialized emulsion formulations.
LIBANG also is one of the leading player in the field of lipid-based formulation research, and has accumulated expertise in liposome, emulsion, PEG, and microsphere related formulation development to solve the most difficult drug delivery challenges and to develop innovative pharmaceutical products.
LIBANG’s range of technologies allows us to offer numerous solutions for any drug delivery problem. Our drug delivery technologies can also be used as innovative and effective life cycle management tools that prolong the market life of drug and pharmaceutical products. In 2003, LIBANG was named National Liposmal Drug Delivery Research Centre
------------Liposomal encapsulation
------------Emulsion
------------Pegylation
------------Micro emulsion
------------Microsphere
Libang has conquered the technical difficulty in synthesis of PEG-liposome, can make alkalescent drugs such as doxorubicin, Vincristine, Mitoxantrone and Ciprofloxacin can be encapsuled into liposome by pH-gradient method, with high liposome entrapment of 99% and the particle size of 100nm.
Vancouver API Laboratory
A 3,400 ft research laboratory was built in 2005
Focuses on research and development of new processes, designed to ensure the non-infringement of patents
A total of 6 people is currently working in the laboratory, 4 of them are Ph.Ds
All Ph.D chemists have over 10 years experiences working in the North America pharmaceutical industry
An excellent record of achievement in the development process and scale up of new molecules
